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PURPOSE: To evaluate whether climacteric women undergoing liver transplantation had higher prevalence of 
decreased bone mass than those without any liver disease. METHODS: A cross-sectional study with 48 women 
receiving follow-up care at a university hospital in Southeastern Brazil, from February 4th 2009 to January 5th 2011, 
was conducted. Of these women, 24 were 35 years or older and had undergone liver transplantation at least 
one year before study entry. The remaining 24 women had no liver disease and their ages and menstrual patterns 
were similar to those of transplanted patients. Laboratorial tests (follicle-stimulating hormone and estradiol) and bone 
density measurements of the lumbar spine and femur (equipment Hologic, Discovery WI) were performed. Statistical 
analysis was carried out by Fisher’s exact test, simple Odds Ratio (OR), and multiple logistic regression. RESULTS: 
Mean age of the women included in the study was 52.8 (±10.7) years-old, 27.1% were premenopausal and 
72.9% were peri/postmenopausal. Approximately 14.6% of these women exhibited osteoporosis and 35.4% had 
low bone mass. The following items were associated with decreased bone mass: being postmenopausal (OR=71.4; 
95%CI 3.8–1,339.7; p<0.0001), current age over 49 years-old (OR=11.4; 95%CI 2.9–44.0; p=0.0002), and 
serum estradiol levels lower than 44.5 pg/mL (OR=18.3; 95%CI 3.4–97.0; p<0.0001). Having a history of liver 
transplantation was not associated with decreased bone mass (OR=1.4; 95%CI 0.4–4.3; p=0.56). CONCLUSION: 
Liver transplantation was not associated with decreased bone mass in this group of climacteric women.
Resumo
OBJETIVO: Avaliar se mulheres climatéricas submetidas a transplante de fígado tiveram maior prevalência de massa 
óssea diminuída do que aquelas sem antecedente de doença hepática. MÉTODOS: Estudo de corte transversal, com 
48 mulheres em acompanhamento ambulatorial em um hospital universitário na região Sudeste do Brasil, no período 
de 04 de fevereiro de 2009 a 05 de janeiro de 2011. Foram incluídas 24 mulheres submetidas a transplante 
hepático há pelo menos um ano, com idades igual ou superior a 35 anos, e 24 sem antecedente de doença hepática, 
com idade (± três anos) e padrão menstrual semelhante ao das transplantadas. As mulheres foram submetidas a 
exames laboratoriais (hormônio folículo estimulante e estradiol) e à densitometria óssea de coluna lombar e fêmur, 
com equipamento Hologic, Discovery WI. A análise estatística foi realizada por meio do teste exato de Fisher, por 
Odds Ratio (OR) simples e pela regressão logística múltipla. RESULTADOS: A média etária das mulheres incluídas no 
estudo foi de 52,8 (±10,7) anos, sendo que 27,1% estavam na pré-menopausa e 72,9%, na peri/pós-menopausa. 
Aproximadamente 14,6% dessas mulheres apresentaram osteoporose e 35,4%, baixa massa óssea. Os seguintes 
itens foram associados com massa óssea diminuída: estar na pós-menopausa (OR=71,4; IC95% 3,8–1.339,7; 
p<0,0001), idade atual maior que 49 anos (OR=11,4; IC95% 2,9–44,0; p=0,0002) e nível de estradiol sérico 
menor que 44,5 pg/mL (OR=18,3; IC95% 3,4–97,0; p<0,0001). Ter antecedente de transplante hepático não se 
associou à massa óssea diminuída (OR=1,4; IC95% 0,4–4,3; p=0,5). CONCLUSÃO: O transplante hepático não 
se associou à massa óssea diminuída nesse grupo de mulheres climatéricas.
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Introduction
Osteoporosis is considered an important com-
plication after liver transplantation1. The majority 
of patients who had liver transplantation develop 
accelerated bone mineral density (BMD) loss in the 
first three to six months following transplantation 
leading to increased fracture risk, owing to preexist-
ing chronic liver disease associated with postsurgical 
administration of high doses of immunosuppres-
sant agents2. Other factors, such as malnutrition, 
hypogonadism, vitamin D deficiency and physical 
inactivity, common in patients with end-stage liver 
disease, may also contribute to loss of bone mineral 
density3. Furthermore, cholestatic diseases, such as 
primary biliary cirrhosis and sclerosing cholangitis, 
have also been described as risk factors for decreased 
bone mass due to possible malabsorption of calcium 
and vitamin D and interference of hyperbilirubine-
mia in the osteoblast function4. In contrast, a more 
recent study suggested that the introduction of bone-
protective therapy and the reduction in the total dose 
of glucocorticoids used for immunosupression might 
lead to decreased incidence of fractures in patients 
undergoing liver transplantation5.
Women currently represent approximately one-
third of patients who undergo liver transplantation. 
Primary biliary cirrhosis, cirrhosis following viral 
hepatitis, and autoimmune hepatitis are the main 
indications for liver transplantation in women6. 
Alcoholism and hepatitis C are also important indi-
cations in Brazil7. Climacteric women have a marked 
reduction in the serum estrogen levels, which is as-
sociated with decreased bone mass after menopause. A 
previous study including women with a history of liver 
transplantation aged >35 years-old demonstrated that 
menopausal status, older current age, and older age 
at the time of transplantation were associated with a 
decreased bone mass. The same study pointed that the 
longer the period after transplantation, the higher 
the bone mass of transplant recipients1. In contrast, 
a previous study identified that age and severity of 
liver disease, however not menopausal status, were the 
main risk factors for the development of osteoporosis 
in women with primary biliary cirrhosis, who were 
not liver-transplanted recipients8.
In the last few years, liver transplantation has 
become an efficient form of treatment for patients 
with severe liver disease. Advances in several aspects 
of medical transplantology have led to an increased 
survival of end-stage liver disease patients9. A larger 
number of women undergoing liver transplantation 
will therefore reach climacteric age. Most studies 
concerning hypogonadism after liver transplantation 
were based on male populations10. With the purpose 
of evaluating whether climacteric women undergo-
ing liver transplantation had higher prevalence of 
decreased bone mass than those without history 
of liver disease, we conducted a study of women re-
ceiving outpatient treatment at a university hospital 
in Southeastern Brazil.
Methods
Cross-sectional study with women undergoing liver 
transplantation receiving treatment follow-up in the 
Liver Transplantation Outpatient Unit of the Hospital 
das Clínicas at University of Campinas (UNICAMP) 
Medical School, and those without liver disease receiv-
ing follow-up treatment in the Menopause Outpatient 
Unit of the Professor Doutor José Aristodemo Pinotti 
Women’s Integrated Healthcare Center (CAISM) of the 
UNICAMP Medical School, from February 4th 2009 to 
January 5th 2011. All women aged 35 years or older 
and who had undergone a liver transplantation at least 
one year before enrollment were included in the study. 
For each liver-transplant patient, a woman matched 
for age (three years, plus or minus) and for menstrual 
cycle pattern was selected for comparison. Women 
were considered postmenopausal when experiencing 
amenorrhea for at least 12 months or when follicle-
stimulating hormone (FSH) was higher than 23 mUI/mL. 
Women were regarded as perimenopausal when pre-
sented menstrual irregularity (with no anatomical 
cause). Women presenting regular menstrual cycles 
were considered premenopausal11. We did not include 
patients who were in debilitating clinical conditions, 
those with personal history of bilateral oophorectomy 
or using hormone therapy for menopausal symptoms or 
contraception in the three months preceding the 
study. Thirty-three liver-transplant patients met 
the inclusion criteria. Of these, five did not respond 
to telephone contact and four declined to participate. 
The final number of transplant recipients participating 
in the study was 24. For each liver- transplant patient, 
one woman without liver disease was selected, who 
was matched for age (three years, plus or minus) and 
menstrual cycle patterns. The final number of women 
included in the study was 48.
Women had interviews in the Menopause Outpatient 
Facility at the CAISM of UNICAMP. Interviews were 
always performed by the same researcher in order to 
collect the following data: age; skin color; formal 
education; marital status; date of transplantation; 
period after transplantation; disease that caused liver 
failure; type of immunosuppressant drug currently 
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in use; presence of arterial hypertension or diabetes 
mellitus; history of smoking; date of menarche; date 
of the last menstruation; menstrual cycle pattern; 
and sexual activity. Weight (kg), height (meters), and 
arterial blood pressure (mmHg) were also measured. 
After the interview, blood samples were taken for 
laboratorial tests (FSH and serum estradiol), and 
BMD measurements at the lumbar spine and femur 
were performed. All patients signed a free written 
informed consent prior to the interview. The study 
was approved by the Research Ethics Committee of 
UNICAMP, under number 721/2008, and funded by 
Fundação de Amparo à Pesquisa do Estado de São Paulo 
(FAPESP), under number 2008/09726-6.
Bone mineral density 
Bone mineral density  measurements at the lumbar 
spine (L1–L4), total femur,  and femoral neck were made 
using a dual energy X-ray absorptiometry scan (Hologic, 
Discovery, WI). The variation coefficient of the device 
was 0.45%. Bone mineral density  measurements were 
expressed in grams per square centimeter (g/cm2) and 
as T- and Z-scores. For BMD measurements, we used 
T-score value for postmenopausal and perimenopausal 
women. For premenopausal women, a Z-score was used12. 
T-score values lower or equivalent to -2.5 were classified 
as osteoporosis. The ones between -1 and -2.5 standard 
deviations were considered as low bone mass. Bone mass 
was considered normal for T-score values above or equal 
to-1 standard deviation13. Z-score values higher than -2 
standard deviations were considered to be within the 
expected range for age, and Z-score values equal or lower 
than -2 standard deviations were considered below the 
expected range for age12. For statistical analysis, values 
of T-score below -1 standard deviation and those of 
Z-score lower or equal to -2 standard deviations were 
considered as decreased bone mass. Values of T-score 
above or equal to -1 standard deviation and values of 
Z-score above -2 standard deviations were considered as 
normal bone mass12,13.
Biochemistry and hormone measurements
After an overnight fast, blood samples were taken 
on the day of the interview from 7 to 10 o’clock 
A.M. The samples were stored in a freezer at -20ºC 
until processing. FSH measurement was obtained 
by chemiluminescence (Advia, Centauro-Siemens), 
with 0.3 mUI/mL as the minimum concentration 
detected. Concentrations higher than 23 mUI/mL 
were regarded as postmenopausal. Serum estradiol 
measurement was also obtained by chemilumines-
cence (Centauro-Siemens), and 7.0 pg/mL was the 
minimum concentration detected.
Statistical analysis
Data were assessed by mean, standard deviation, and 
median. For laboratory or time-interval measurements, 
the median was used as the cutoff point, and analysis was 
performed with categories above and below the median, 
using Fisher’s exact test, simple Odds Ratio (OR), and 
multiple logistic regression analysis with stepwise variable 
selection. The significance level was set at 5% and SAS 
version 9.1.3 was the software used for analysis.
Results
The clinical social and demographic data of women 
included in this study are shown in Table 1. The mean age 
was 52.8±10.7 years-old (median 49.9, range 35.0–72.2). 
Among the patients, 6 (12.5%) were 35 to 40 years-old, 
6 (12.5%) were 40 to 45 years-old, 12 (25%) were 45 
to 50 years-old, 2 (4.2%) were 50 to 55 years-old, 7 
(14.6%) were 55 to 60 years-old, 6 (12.5%) were 60 to 
65 years-old, 8 (16,7%) were 65 to 70 years-old, and 1 
(2.1%) was 70 to 75 years-old. The mean patient age at 
liver transplantation was 46.0±12.3 years-old (median 
43.4, range 25.7–63.9). The mean time since transplan-
tation was 6.1±3.3 years (median 5.8, range 1–12.5). 
The mean body mass index was 27.6±4.7 (median 27.0, 
range 18.8–40.9). Of the 48 women, 13 (27.1%) were 
premenopausal, 5 (10.4%) were perimenopausal and 30 
(62.5%) were postmenopausal. Corticosteroid was used 
as an immunosuppressant agent by 8 women (16.7 %) 
and 40 (83.3%) were not taking corticosteroid. 
Among the 48 women included in the study, 24 had 
decreased bone mass (50%). Of these, seven (14.6%) 
had osteoporosis diagnosed by BMD measurement 
(with five (10.4%) at one or more measured sites and 
two (4.2%) at the lumbar spine, femoral neck and total 
femur), and 17 had low bone mass at one or more sites 
measured (35.4%). Of the 24 liver-transplant recipients, 
13 (54.2%) had decreased bone mass, five (20.8%) had 
osteoporosis diagnosed by BMD measurement at one or 
more sites measured, and 8 (33.3%) had low bone mass 
at one or more sites measured. Of the 24 women without 
liver disease, 11 (45.8%) had decreased bone mass, 2 
(8.3%) with osteoporosis diagnosed by BMD measure-
ment at one or more sites measured and 9 (37.5%) with 
low bone mass at one or more sites measured (Table 1).
Being postmenopausal (OR=71.4; 95%CI 3.8–1339.7; 
p<0.0001) was significantly associated with decreased 
bone mass. The age of woman at the time of the interview 
was significantly correlated, and age over 49 was highly 
associated with decreased bone mass (OR=11.4; 95%CI 
2.9–44.0; p=0.0002). Serum estradiol levels lower than 
44.5 pg/mL were also associated with decreased bone 
mass (OR=18.3; 95%CI 3.4–97.0; p<0.0001).
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There was no statistically significant difference in 
bone mass values between the group with history of 
liver transplantation and the one without it (OR=1.4; 
95%CI 0.4–4.3; p=0.5).
All liver transplant recipients were taking immu-
nosuppressant medication. Of these women, 8 (16.7%) 
used tacrolimus and mycophenolate, 4 (8.3%) used 
tacrolimus alone, 3 (6.25%) used cyclosporine alone, 3 
(6.25%) used tacrolimus and prednisone, 1 (2.1%) used 
cyclosporine and prednisone, 1 (2,1%) used cyclosporine 
and mycophenolate, 2 (4.2%) used tacrolimus, predni-
sone and mycophenolate, 1 (2.1%) used cyclosporine, 
prednisone and mycophenolate, and 1 (2.1%) used 
tacrolimus, prednisone and azathioprine. None of the 
study participants without liver disease used any type 
of immunosuppressant drug. Owing to a small sample, 
the diverse combinations of immunosuppressant agents 
and the fact that glucocorticoids are most strongly 
linked to decreased bone mass, we chose to subdivide 
these women into two groups. One of them was com-
posed of steroid users (83.3%), and the other did not 
use them (16.7%). There was no significant difference 
between both groups concerning bone mass (OR=0.2; 
95%CI 0.05–1.5; p=0.2). 
The associations between bone mass and skin color, 
marital status, arterial hypertension, diabetes mellitus, 
smoking, age at menarche, sexual activity, body mass 
index, and parity were not significant (Table 2).
Table 1. Clinical and social demographic data and bone mineral density, according to the World Health Organization criteria (n=48)
Osteoporosis: T-score ≤ -2.5 standard-deviations; Low bone mass: T-score values between -1 and -2.5 standard-deviations; Normal: T-score > -1 standard-deviation.
Liver Transplantation Control
Premenopausal Peri/postmenopausal Premenopausal Peri/postmenopausal
  n % n % n % n %
Color    
White 7 100.0 13 76.5 2 33.3 11 61.1
Non-white 0 0.0 4 23.5 4 66.7 7 38.9
Schooling    
0–7 years 4 57.1 10 58.8 4 66.7 14 77.8
8–12 years 2 28.6 5 29.4 2 33.3 4 22.2
>12 years 1 14.3 2 11.8 0 0.0 0 0.0
Marital Status    
With partner 6 85.7 8 47.1 4 66.7 14 77.8
Hypertension    
Yes 1 14.3 3 17.6 0 0.0 11 61.1
Diabetes Mellitus    
Yes 0 0.0 5 29.4 0 0.0 2 11.1
Sexual Activity    
Yes 7 100.0 9 52.9 5 83.3 11 61.1
Immunosupression    
With corticosteroids 4 57.1 4 23.5 0 0.0 0 0.0
Parity    
0 2 28.6 1 5.9 1 16.7 2 11.1
1 4 57.1 5 29.4 3 50.0 2 11.1
≥2 1 14.3 11 64.7 2 33.3 14 77.8
Smoking    
Yes 1 14.3 0 0.0 1 16.7 2 11.1
Femoral neck    
Osteoporosis 0 0.0 3 17.6 0 0.0 2 11.1
Low bone mass 0 0.0 9 52.9 0 0.0 4 22.2
Normal 7 100.0 5 29.4 6 100.0 12 66.7
Total femur    
Osteoporosis 0 0.0 2 11.8 0 0.0 0 0.0
Low bone mass 0 0.0 7 41.2 0 0.0 3 16.7
Normal 7 100.0 8 47.1 6 100.0 15 83.3
Lumbar spine (L1–L4)    
Osteoporosis 0 0.0 4 23.5 0 0.0 1 5.6
Low bone mass 0 0.0 5 29.4 0 0.0 8 44.4
Normal 7 100.0 8 47.1 6 100.0 9 50.0
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Bone mass
OR 95%CIDecreased Normal p-value
n % n %
Group 0.56
Control 11 45.8 13 54.2 1.0
Liver transplantation 13 54.2 11 45.8 1.4 0.4–4.3
Age <0.01
≤49 years-old 5 20.8 18 75.0 1.0
>49 years-old 19 79.2 6 25.0 11.4 2.9–44.0
Color 0.11
White 19 79.2 14 58.3 2.7 0.7–9.7
Non-white 5 20.8 10 41.7 1.0
Marital status 0.22
With partner 14 58.3 18 75.0 1.0
Without partner 10 41.7 6 25.0 2.1 0.6–7.3
Hypertension 0.75
Yes 8 33.3 7 29.2 1.2 0.3–4.1
No 16 66.7 17 70.8 1.0
Diabetes mellitus 0.41*
Yes 5 20.8 2 8.3 2.8 0.5–16.6
No 19 79.2 22 91.7 1.0
Menopausal status <0.01*
Premenopausal 0 0.0 13 54.2 1.0
Perimenopausal 2 8.3 3 12.5 19.2 0.7–500.4
Menopausal 22 91.7 8 33.3 71.4 3.8–1339.7
Menarche 0.55
≤13 years 13 54.2 15 62.5 1.0
>13 years 11 45.8 9 37.5 1.4 0.4–4.4
Sexual activity 0.06
Yes 13 54.2 15 62.5 0.7 0.2–2.2
No 11 45.8 9 37.5 1.0
Body mass index 0.24
≤27 14 58.3 10 41.7 1.0
>27 10 41.7 14 58.3 0.5 0.1–1.6
Immunosupression 0.24*
Without corticosteroids 22 91.7 18 75.0 1.0
With corticosteroids 2 8.3 6 25.0 0.2 0.05–1.5
Parity 0.54*
0 2 8.3 4 16.7 1.0
1 6 25.0 8 33.3 1.3 0.2–8.7
≥2 16 66.7 12 50.0 2.3 0.4–13.1
Estradiol <0.01
<44.5 pg/mL 22 91.7 9 37.5 18.3 3.4–97.0
≥44.5 pg/mL 2 8.3 15 62.5 1.0
Smoking 0.6*
Yes 1 4.2 3 12.5 1.0
No 23 95.8 21 87.5 3.2 0.3–34.0
Table 2. Factors associated with decreased bone mass (n=48)
Decreased bone mass: T-score <-1 standard deviations or Z-score ≤-2 standard deviations. *Fisher’s exact test.
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Discussion
The aim of this study was to assess whether climac-
teric women undergoing liver transplantation had higher 
prevalence of decreased bone mass than those without 
it. The prevalence rate of decreased bone mass (54.2%) 
and osteoporosis (20.8%) in women with a history of 
liver transplantation in the present study was slightly 
lower than the rate reported previously in the literature, 
which is around 65.5% of decreased bone mass14 and 
25 to 50% of osteoporosis diagnosed by BMD measure-
ment15,16. In the group of women without liver disease, 
the prevalence of decreased bone mass (45.8%) was 
similar to that previously estimated, which is between 
37 and 50% of the cases17. There were no significant 
differences between the rates of decreased bone mass in 
women with a search history of liver transplantation and 
those without a search history. 
Previous data have shown that loss of bone mass 
occurs especially in the first three to six months 
following liver transplantation18-20. Studies of bone 
histology have shown that bone loss ceases approxi-
mately six months after liver transplantation. Bone 
formation tends to increase later, especially at the 
lumbar spine, leading to restoration of bone mass up 
to two years after surgery9. A previous study1 showed 
a clear tendency towards increased bone mass at the 
lumbar spine, as time since transplantation increased. 
The same study observed a less intense correlation 
between bone mass at the femoral neck and time 
since transplantation. Previous studies showed that 
restoration of bone mass was slower at the femoral 
neck than at the lumbar spine. It is likely that cortical 
bone requires more time to recover than the trabecular 
one14,18. The mean time since transplantation in the 
present study was 6.1±3.3 years. We believe that a 
high mean time elapsed since surgery was the major 
factor associated with the lack of a significant differ-
ence in bone mass, between liver transplant patients 
and the nontransplant ones. 
The relationship between menopausal status and 
bone mass in patients with chronic liver disease is not 
fully understood. A study with subjects who had re-
ceived a liver transplant observed correlations between 
menopausal status and chronological age. However, 
the authors did not observe a significant influence of 
menopausal status on bone mass18. A study including 
nontransplant patients with primary biliary cirrhosis 
concluded that menopausal status was not an indepen-
dent risk factor for osteoporosis, however independent 
factors were chronological age, severity of liver disease, 
advanced histologic stage, and low body mass index8. A 
more recent study with only women undergoing liver 
transplantation found an inverse correlation between 
BMD and length of amenorrhea expressed in months 
after the last menstruation, i.e., the longer the time since 
onset of menopause, the lower the BMD1. Decreased 
bone mass was not observed in any premenopausal 
women, regardless of receiving or not a liver transplant. 
In perimenopausal and postmenopausal women with 
history of liver transplantation, decreased bone mass 
was found in 76.5% of the cases, and osteoporosis was 
diagnosed in 29.4% of them. 
The prevalence of osteoporosis in climacteric 
transplant recipients in the present study was lower 
than the result reported by a previous study, which 
described osteoporosis in 50% of patients undergoing 
liver transplantation in the postmenopause. However, 
it is worth mentioning that in this study approximately 
94% of climacteric transplant recipients were taking 
glucocorticoids16. In contrast, only 23.5% of them were 
using corticosteroids in the present study. In control 
perimenopausal and postmenopausal women, decreased 
bone mass was present in 61.1%, and osteoporosis was 
diagnosed by BMD measurement in 11.1% of women. We 
observed a significant association between postmenopausal 
status, serum estradiol levels lower than 44.5 pg/mL, 
and decreased bone mass. Such data have led us to be-
lieve that menopausal status is indeed one of the main 
factors associated with higher prevalence of decreased 
bone mass, both in liver transplant patients and in 
women without a history of liver disease. A noteworthy 
result observed in the present study was that there was 
no decreased bone mass in any of the premenopausal 
women undergoing transplantation. This finding is in 
agreement with previously reported data in the literature, 
which indicates that gain in bone mass during the first 
two years after transplantation was significantly higher 
in premenopausal women compared to that observed in 
perimenopausal and postmenopausal patients, probably 
due to high estrogen levels in these women19.
The deleterious effect of glucocorticoids on bone 
mass has already been previously demonstrated21-29. In 
the present study, the current use of corticosteroid as an 
immunosuppressant did not affect bone mass in liver 
transplant recipients, probably due to time elapsed since 
the transplant. Similar results were also obtained in pre-
vious studies14,18,19. A likely explanation for this finding 
could be that high-dose steroid therapy is administered 
especially in the first months following transplantation, 
causing a higher loss of bone mass in the first months after 
the procedure26. In the following years, the trend will be 
to decrease the total dose of glucocorticoids used, mainly 
because of its combination with tacrolimus28,30, resulting 
in a less significant influence on bone mass. The effects 
of reduced total dose of glucocorticoids could already be 
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observed in a recent study that found decreased incidence 
of fractures in patients undergoing liver transplantation, 
in the period from 1998 to 20085.
We highlight that this study assessed women with 
positive history of liver transplantation aged 35 years or 
older and a Control Group with negative history of liver 
disease, matched for age and menstrual cycle pattern. The 
number of subjects included in each subgroup was small, 
which can reduce the strength of statistical results and 
cannot be generalized to other groups of liver transplant 
recipients or other populations. However, we believe 
that a comparison of a group of women with history of 
liver transplantation and a group of women with healthy 
livers is of great importance to better comprehend hypo-
gonadism following transplantation and its interference 
in bone mass. 
The present study showed that menopausal status, 
older current age, and lower serum estradiol levels were the 
major factors associated with decreased bone mass in the 
female group evaluated. There was no difference in BMD 
between the group with history of liver transplantation 
and the Control Group, probably due to a high mean time 
period after transplantation in the transplant recipient 
group. This topic has still not been thoroughly studied 
and fully understood. We believe that reported data may 
help to understand the behavior of bone mass in women 
undergoing liver transplantation. Further studies are 
necessary, since the number of transplantations performed 
continues to grow.
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